Successful Virilization of a PAIS Patient with a Missense Mutation in the Ligand-Binding Domain of the Androgen Receptor Using Combined High-Dose Testosterone and Aromatase Inhibitor

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

The conversation is about managing potential gynecomastia from finasteride use. The user considers using an aromatase inhibitor and plans to check hormone levels.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Androsterone may help with sexual and affective dysfunction from finasteride by replacing disrupted neurosteroids without increasing androgenic side effects. Controlled testing is needed to confirm its effectiveness and safety.

The user experienced side effects from spironolactone and is seeking alternatives for androgenetic alopecia (AGA), considering saw palmetto but unsure of its effectiveness. They are also exploring the possibility of using topical spironolactone, despite availability challenges.